全球OTC藥物市場(chǎng)調(diào)研和分析報(bào)告（英文版）-2024年1月上傳培訓(xùn)課件

INDUSTRIES

&

MARKETSOTC

Pharmaceuticals:

marketdata

&

analysisMarket

InsightsreportOctober2023Table

of

ContentsOverviewMarket

DefinitionMarkets56HandSanitizerEyeCare61677277KeyTakeawaysSalesFiguresRegionalComparisonDrivers9SleepAids101213WoundCareAppendixProductOverviewAuthor8384ConsumerInsightsSummary1920RegionalComparisonKey

PlayersCompanyProfilesTrends2528MarketsAnalgesics3137434955Cold&CoughRemediesDigestives&IntestinalRemediesSkinTreatmentVitamins&

Minerals2MARKET

INSIGHTSThis

report

is

part

ofour

Market

Insights

productGainabetterunderstandingofmarketsacross190+

geographicalentities

–

onaglobal,

regional,country,

and/orstatelevel.

Accessourdatavia

webinterface,download(XLS,

PDF,PPT),or

reports.Benefitfromour48-hourcustomerservice

guarantee.?

10

sectors:

advertising&media,consumers,countries,digital

sector,finance,health,

industrialsector,mobility,andtechnology?

1,000+

markets,

e.g.,

FinTech,Food,or

Robotics?

KPIs,

e.g.,

revenue,marketshares,prices,andvolume?

Features:Compare

countries®ions,

change

currencies,

selectvisualizations,

and/or

customize

downloads?

Usecases:

sales

planning,

investment

decision

support,resourceallocation,andportfolio

management10sectors190+geographicalentities1,000+markets400+reportsFind

out

more

on:https://www.Goto

Market

Insightscom/outlook/3CHAPTER

1OverviewThe

OTC

Pharmaceuticals

market

is

a

steadily

growing

market,

heavilydependent

on

national

legislationOverview:

Market

DefinitionTheOver-the-counter

(OTC)Pharmaceuticals

market

comprises

prescription-freemedicines.

Inthis

report,

growth

potentials,market

drivers,

consumer

insights,keycompanies,

and

futuredevelopments

forthree

major

OTCPharmaceutical

markets,America,

Europe,

and

Asia,will

bediscussed.Next

tothe

access

tohealthcare,

theconsumer

attitudesand

behavior

regardingmedication

alsodiffersignificantlyfrom

countrytocountry.

Attitudestowardsmedication,

frequency

ofmedication

intakeandtheextent

towhich

people

trustmedical

adviceon

the

internet

are

justafew

ofthetopicsdiscussed

withintheconsumer

insightssection.Themarket

isdivided

into

tenmarkets:

Analgesics,

Cough&Cold

Remedies,Digestives

&IntestinalRemedies,

SkinTreatment,

Vitamins&Minerals,

HandSanitizer,Eye

Care,Sleep

Aids,

Wound

Care,andOtherOTCPharmaceuticals.Thegrowing

numberof

internet

andsmartphone

users

hasnotonly

changedconsumer

behavior,

ithasalsofundamentallyreshaped

thesaleschannels

andretail

landscape.

For

different

reasons,

theonlineshare

inthe

OTCPharmaceuticals

market

varies

significantlybetween

countries.

Among

theimportant

drivers

are

the

access

tomedicine

and

thedevelopment

of

theeCommerce

market

ingeneral,

butthemost

decisive

factoristhelegislation

ineach

country.Various

market

drivers

influence

theOTCPharmaceuticals

market.

Theworldwideimprovement

inaccess

to

healthcare

andpharmaceuticalshasdirect

effects

on

theOTCPharmaceuticals

sales.

Good

measures

of

thesedrivers

aretheGlobal

AccesstoHealthcare

Index

and

theHuman

Development

Index.

Generally

speaking,thebetter

theaccess

tomedicine,

themore

medicine

istaken.

However,

asaccess

tomedicines

varies

considerably

from

country

to

country,factorssuchas

the

politicalwill

toimprove

thehealthcare

system

canalsoinfluence

themarket

forecast.OTCPharmaceuticals

trendscontinueinthedirection

of

naturalingredientswithout

alcohol,

artificialadditivesor

gluten.

In

additiontonaturalmedicines,

thetrend

towards

connected

devices

and

eHealth

becomes

more

andmoreimportant

inthefield

ofhealthcare.5Sources:Market

Insights

2023The

OTC

market

includes

Analgesics,

Cold

&

Cough

Remedies

and

Digestives

&Intestinal

RemediesOverview:

Markets

(1/3)AnalgesicsCold

&Cough

RemediesDigestives&Intestinal

RemediesTheAnalgesicsmarket

comprises

over-the-counternaturaland

syntheticnon-opioid

analgesics

(only

inapproved

low

doses)

likeParacetamol,

Ibuprofen,Aspirinandotherpain-relieving

preparations.Legislation

onopioid

analgesicsdiffersfrom

countryTheCold&Coughmarket

comprises

over-the-counternaturaland

syntheticagentsto

relieve

cough,expectorants

and

sore

throatremedies,

cold

remediesandpreparations

againstflu-like

infections.

ItincludesThe&IntestinalRemedies

market

comprises

over-the-counter

naturaland

syntheticdigestive

agentsandremedies

againstgastrointestinal

complaints.

Itincludespreparations

inthe

form

ofpills,powder,medicines

intheform

ofpills,syrups,lozenges,

sprays,

capsules,liquids,solutions,

suspensions,

drops

andtocountry.

Analgesicsareincluded

inthe

form

ofpills,

ointments

and

granulateforexternal

and

internalcapsules,gels

and

ointments.

application.suppositories.

Not

includedare

prescriptionmedicines.6Sources:Market

Insights

2023The

OTC

market

includes

Skin

Treatment,

Vitamins

&

Minerals

and

HandSanitizerOverview:

Markets

(2/3)SkinTreatmentVitamins

&MineralsHandSanitizerTheSkinTreatment

market

comprises

over-the-counter

naturaland

syntheticmedical

skin

treatmentproducts

likeantibacterial

preparations,

acnetreatment

agents,antifungals.

Preparations

forskinTheVitaminsandMinerals

market

comprises

over-the-

Handsanitizer,

alsoknown

ashandantiseptic,is

acounter

naturaland

syntheticfood

supplements

likemultivitamin

preparations,

minerals,

vitamins,tonicsandcodliver

oil.

Vitaminsandminerals

includefoam,gel

or

liquid-based

sanitizingagentthatisappliedon

hands

for

removing

various

disease-causingpathogens.

Itincludesbothproductswhichareexclusively

sold

inpharmacies

andproductswhichcanbepurchased

elsewhere.

Sales

byhospitalsarenotincluded.treatment

includemedicines

intheformof

ointments,

preparations

intheform

of

capsules,dragees,

pills,creams,

gels,pills,capsules,

washing

lotions,peelings,pastes,solutions,

fluids,

suppositories

andsprays

forexternal

andinternalapplication.granulate,ampoules,

solutions,

powders,

syrupsfororal

use.7Sources:Market

Insights

2023The

OTC

market

includes

Eye

Care,

SleepAids

and

Wound

CareOverview:

Markets

(3/3)Eye

CareSleepAidsWoundCareTheEyeCaremarket

encompasses

adiverse

array

ofover-the-counter

therapeutic

and

hygiene

productsspecifically

formulated

to

address

minoreye

dryness,irritation,andvariousdiscomforts

andailments.

Thiscategory

includeseye

drops,

eye

ointments,andeyewashes,

all

tailored

to

provide

relief,

moisture,

andcleansing

fortheeyes.TheSleep

Aids

market

encompasses

adiverse

array

ofover-the-counter

(OTC)medications

andsupplementsdesigned

to

aidindividualsinmanagingsleep-relateddisorders,

includinginsomnia,sporadicsleepdisruptions,and

jetlag

resulting

from

adjustingtodifferent

time

zones.

Thismarket

includesproductscontainingingredients

suchasDoxylamine

Succinate,Diphenhydramine,

Melatonin,

andherbalremedies.TheWoundCare

market

consists

ofacomprehensivearray

of

over-the-counter

(OTC)solutions.

Thesesolutions

areaimed

atmanagingwounds,

promotinghealing,and

preventing

infections.

Theproductofferings

encompass

adhesive

bandagesforminorwound

coverage,

firstaidkitsproviding

extensivesupplies,gauzeandtape

formaintainingcleanliness,aswell

aswound

healing

ointmentsthatsupport

therecovery

of

damaged

skinandwounds.8Sources:Market

Insights

2023With

21%,

Cold

&

Cough

Remedies

market

accounts

for

the

biggest

share

in

theOTC

marketOverview:

Key

TakeawaysWorldwide

revenue

share

in2022Revenue

intheOTC

Pharmaceuticals

market

amountstoUS$184.30bn

in2022.

Themarket

isexpected

to

grow

annuallyby4.76%

(CAGR

(1)

2023-2028).15%15%Themarket's

largest

market

isthe

market

Cold&CoughRemedies

with

amarketvolume

of

US$38.79bn

in2022.10%10%Inglobalcomparison,

most

revenue

isgenerated

intheUnited

States(US$37,610.00m

in2022).20%Inrelation

to

totalpopulation

figures,per

person

revenues

of

US$24.18

aregenerated

in2022.IntheOTCPharmaceuticals

market,

26%

oftotal

revenue

will

begenerated

throughonlinesales

by2022.3%3%2%2%21%Skin

TreatmentCold&Cough

RemediesWoundCareOtherOTC

PharmaceuticalsVitamins&MineralsAnalgesicsDigestives&IntestinalRemediesEyeCareSleepAidsHandSanitizer9Notes:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023Sources:In2022,

the

OTC

Pharmaceuticals

market

realized

a

revenue

of

US$184.3

billionworldwideOverview:

Sales

Figures(1/2)Worldwide

OTCPharmaceuticals

revenue

inbillionUS$243.6233.141.1222.538.5212.236.143.6202.433.8193.131.6184.329.7176.628.0168.225.6164.125.6158.024.156.021.4152.122.752.920.849.720.3144.821.046.719.743.919.141.318.638.818.236.717.832.717.36.23.76.03.635.117.75.83.533.017.331.317.05.73.35.53.229.216.45.43.15.23.05.23.54.30.94.96.34.71.04.81.038.124.538.525.84.51.037.723.237.222.036.720.836.219.728.635.718.826.835.317.125.134.516.334.416.134.415.834.015.320.0

3.233.6

14.46.05.95.73.55.63.55.43.42.83.13.33.64.14.53.44.93.45.23.434.636.73.538.83.530.632.518.9

3.221.2

3.322.2

3.323.5

3.32016201720182019202020212022202320242025202620272028AnalgesicsDigestives

&IntestinalRemediesEyeCareHandSanitizerOtherOTCPharmaceuticalsSkinTreatmentSleep

AidsVitamins&MineralsWound

CareCold&CoughRemedies10Sources:Market

Insights

2023The

Analgesics

market

has

the

highest

growth

potential

with

47%

from2022

to2028Overview:

Sales

Figures(2/2)Worldwide

revenue

inbillion

US$+44%(1)+47%(1)43.656.0+8%(1)38.5+45%(1)38.838.8+38%(1)25.835.7+18%(1)21.429.726.818.818.2+18%(1)6.2+23%(1)6.0+26%(1)3.7+4%(1)3.5Wound

Care5.24.93.03.4AnalgesicsCold&CoughRemediesDigestives&IntestinalRemediesEyeCareHandSanitizer2022OtherOTCPharmaceuticalsSkinTreatmentSleep

AidsVitamins&Minerals202811

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023With

a

revenue

of

US$

37.6

billion,

the

United

States

is

the

biggest

marketamong

selected

countries

in

2022Regional

Comparison:

GlobalRevenue

forecast

inbillionUS$+3.7%(1)+6.1%(1)46.840.637.628.5+2.7%(1)+8.2%(1)+3.2%(1)11.29.510.010.28.36.32022202820222028202220282022202820222028United

StatesChinaGermanyJapanIndia12

Notes:Sources:(1)

CAGR:

Compound

Annual

GrowthRateMarket

Insights

2023The

Global

Access

to

Healthcare

Indexand

the

Human

Development

Indexcorrelate

with

OTC

salesDrivers:

SummaryTheaccess

to

healthcare

hasstrongly

improved

inrecent

years

and

more

peoplethan

ever

inhistory

haveaccess

to

essential

health

services

nowadays.

Oneofthemainreasons

forabetter

populationhealthis

the

improved

drinkingwater

supply.Inadditionto

that,

especially

countries

with

alower-resources

setting

areimproving

theiraccess

to

healthcare

byfocusing

onpreventive

andprimary

care.Thissteady

improvement

inhumandevelopment

and

access

tomedicines

willcontinuetoimpactthe

OTCPharmaceuticals

market.

Particularly

strong

growth

isexpected

inmiddle-income

countries,

astheinfrastructureis

beingfurtherexpanded.

Butover-the-counter

pharmaceuticals

will

continueto

show

highpositive

growth

inOECDcountries

aswell,

aspatientsoften

receive

preventiveservices.There

are

twokey

indicatorsthatreflect

those

drivers

and

thushaveabiginfluenceon

market

forecasts

inthe

OTCmarket:

the

Global

Access

toHealthcare

IndexandtheHuman

Development

Index.Other

factorsalsoinfluencethemarketdevelopment,

including

theshareof

healthexpenditure

inGDP,therise

ofmajorcitiesandthe

maturing

ofthebusinessenvironment.13Sources:Market

Insights

2023,

UNDP,The

Economist–

Intelligence

Unit2017The

increasing

prevalence

of

chronic

diseases

have

led

to

an

increased

demandfor

OTC

marketsDrivers:

chronic

diseasesObesityadultsinmillionsThesurgeinchronic

diseases

isintricately

intertwined

with

the

global

prevalence

ofobesity.

Over

thepastfew

years,

there

hasbeen

anoteworthy

uptickinthepopulationof

adultsgrappling

with

obesity,

with

numbersescalating

bymore

than17%.

In2016,

thecountstood

at689

million,

and

by2022,

ithadsoared

toastaggering

805

million.

Consequently,theworldwide

prevalence

of

obesity

reached24%

by2022,

implyingthatalmost

oneinevery

fiveadults

contends

withthishealthissue.300Asia2502000AmericansEuropeUnhealthy

lifestyles,

marked

byalackof

physicalactivity,subpardietary

choices,andsmoking,are

significantcontributors

toobesity

andthesubsequent

onset

ofchronic

ailments

likeasthma,diabetes,

and

cancer.

Thenumberof

diabetescases,forinstance,witnessed

asurgeof

over

30%

between

2016

and2022,

leapingfrom365

million

to476

million.

While

developed

nationsliketheUnited

Statesexperienced

relatively

modest

increments,

developing

regions

observed

arapidescalation

indiabeticpatients.

Inthecaseof

China,

forinstance,thenumber

ofindividualsafflictedbydiabetesnearly

tripledover

thepastdecade.

Thisupsurgecanbeattributednotonly

to

unhealthylifestyles

but

alsoto

factors

suchaswork-related

stress

and

exposure

topollution,leading

to

anincreased

demand

forover-the-counter

medications.2016201720182019202020212022Diabetespatients(ages20-79)

inmillions500World400100ChinaU.S.0201620172018201920202021202214

Notes:Sources:based

onWorldDiabetes

Federation,

WorldBankThe

Human

Development

Index

demonstrates

a

country’s

current

social

andeconomic

situationDrivers:

HumanDevelopment

Index

(1/3)TheHumanDevelopment

Index(HDI)iscomposed

ofthree

dimensions,

allofwhichareequally

weighted:

health,education,andstandard

of

living.These

dimensionsincludethe

indicatorslifeexpectancy

atbirth,expected

years

of

schooling

andmean

years

of

schooling,

aswell

asgross

nationalincome

(GNI)per

capita.TheHDIcovers

188

countries

worldwide

–

representing

adiversity

of

income

levels.Human

DevelopmentIndex

(1)

in2015OECDcountries20.89Europe&CentralAsia0.760.75TheHumanDevelopment

Index

provides

agood

insightinto

acountry's

currentsocial

andeconomic

situation.

Humandevelopment

isclosely

linkedtoaccess

tohealthcare.

Thisexplainsthe

close

correlation

between

the

HDIand

theGlobalAccess

to

Healthcare

Index.Both

indicesare

basedon

theassumptionthathumandevelopment

isinfluenced

bymanyfactors,

including

infrastructure,

education,andpoverty.

Correspondingly,

countries

scale

similarly

highor

low

inthecomparison

ofthe

two

indices.LatinAmerica&CaribbeanEast

Asia&Pacific0.72ArabStates0.69Similartothe

results

oftheGlobal

Access

to

Healthcare

Index,OECDcountries

likeNorway,

Australia,Switzerland,

andGermany

rank

atthetopof

the

HDI.

TheHumanDevelopment

Index

and

itsrelated

factorsreveal

thedevelopmentpotential

ofthecountries

and

what

opportunities

and

challenges

thereare

forthepharmaceutical

industry.SouthAsia0.62Sub-SaharanAfrica0.5215

Notes:(1)(2)Score

0-1,

where

1=bestOECD

member

countriesSources:

UNDP2018The

Human

Development

Index

correlates

closely

with

the

Global

HealthcareIndexDrivers:

HumanDevelopment

Index

(2/3)Correlation

betweentheHDI

(1)

andtheGlobal

AccesstoHealthcare

Index

(2)10NetherlandsSpainGermanyFrance9876543210CubaCanadaMexicoBrazilColombiaItalyIsraelAustraliaThailandJapanChilePolandArgentinaRomaniaPhilippinesIndiaChinaEcuadorSaudiArabiaIndonesiaSouthAfricaPakistanNepalKenyaEthiopiaNigeriaCambodia0.50.60.7HumanDevelopment

Index0.80.91.016

Notes:(1)(2)Score

0-1,

where

1=bestScore

0-10,

where

10=bestSources:

UNDP2018,

The

Economist

–

Intelligence

Unit2017Italy

and

Slovakia

have

the

highest

HDI

scoresDrivers:

HumanDevelopment

Index

(3/3)Top5countrieswithintheHDIgroups

(1)Very

high

humandevelopmentHighhumandevelopmentMedium

humandevelopmentLow

humandevelopment0.960.950.950.940.940.800.790.790.790.780.690.680.680.680.670.540.540.530.520.5217

Notes:(1)HDIgroups:

very

high

human

development:

>0.799;

high

human

development:

0.798-0.700;

medium

human

development:

0.699-0.556;

low

human

development:

<0.546;

Score0-1,

where1=best

OECD

membercountriesSources:

UNDP2018CHAPTER

2Consumer

InsightsConsumer

attitudes

and

behavior

regarding

medication

differ

significantly

fromcountry

to

countryConsumer

Insights:SummaryTheGlobal

Consumer

Survey

shows

thattheconsumers’

attitudesandbehaviorregarding

medication

and

healthdifferfrom

country

to

country.

InGermany

andtheUnited

States,forexample,

around45

%of

thepopulation

undergoregular

medicalcheck-ups,

ascompared

to

only

25%

inthe

UK.

Still,around45%

of

consumers

inallthree

countries

dosomething

topreserve

theirhealth.IntheUnited

States,Germany,

and

theUnitedKingdommore

than

60%

of

respondentshavetakenvitaminsfood

supplements

inthepast12

months.

Onthe

other

hand,

19-27%

oftherespondents

intheU.S.,Germany

and

United

Kingdom

never

takeany

foodsupplementsWhile

comparing

thehealthcare

procedures

inthelast12

months,more

than60%

ofGerman

respondents

haveconsulted

afamilydoctor

whereas

theaverage

dropped

to45%

forrespondents

from

theU.S.and

theUK.Notably,around10%

of

consumers

inallthree

countries

underwent

surgery

inthelast12

months.Around60%

of

respondents

inthe

U.S.,Germany

andUnitedKingdomhaveexperiencedpainincluding

backpain,headacheandjointpaininthe

last12

months.

Sleep

disordersandmental

healthproblems

areanothertwo

key

areas

where

andaverage

of

40%

ofconsumers

inallthree

countries

haveexperienced

symptoms.19Sources:ConsumerInsights

2023Only

25%

of

British

online

consumers

regularly

undergo

medical

check-upsConsumer

Insights:Regional

Comparison

(1/4)Attitudestowards

healthcareIwouldliketodomore

formyhealth53%55%48%45%Iundergo

regular

medicalcheck-ups47%25%43%43%Iactively

do49%somethingtopreservemyhealthPatientsmustpaytoomuchformedicationandmedicaltreatmentIcouldimagineconsultingdoc-torsvia

anapporanonlinechatIcan

imaginetakingmedicalcannabisfortreatment40%38%38%40%16%47%34%33%39%29%Thehealthsystem

frequentlyletspatientsdown36%35%Ihavelittletrustinthesafetyofvaccinations22%20%20%14%16%Ipreferalternativehealingmet-hodstoconventional

medicine12%4%

7%6%NoneoftheaboveUnitedStatesGermanyUnitedKingdom20

Notes:Sources:"Which

ofthese

statements

do

youagree

with?“;

Multi

Pick;n=

50,398ConsumerInsights

202319-27%

of

the

respondents

in

the

U.S.,

Germany

and

United

Kingdom

nevertake

any

food

supplementsConsumer

Insights:Regional

Comparison

(2/4)Type

of

food

supplements

taken69%VitaminsProteins57%64%28%21%19%24%Minerals33%19%22%17%16%18%HerbsorherbalproductsAnimalsupplements(e.g.fishoil)10%14%13%14%Plantbasedsupplements(e.g.algaloil)9%4%Other6%2%19%Ihavenottakenanyfoodsupplements27%27%UnitedStatesGermanyUnitedKingdom21

Notes:Sources:"Which

types

offoodsupplements

have

youtaken

in

the

past

12

months?“;

Multi

Pick;n=

50,398ConsumerInsights

202330-46%

of

the

respondents

in

the

U.S.,

Germany

and

United

Kingdomunderwent

medical

check-upConsumer

Insights:Regional

Comparison

(3/4)Healthcare

activities46%46%Underwenta39%medical

check-up30%30%44%ConsultedafamilydoctorConsultedaspecialist61%51%21%13%Underwentoutpatienttreatmentinahospital10%10%16%16%Underwentinpatienttreatmentinahospital11%8%10%11%Underwentsurgery7%9%Consultedanalternativepractitioner7%6%26%Noneofthe

above31%UnitedKingdomUnitedStatesGermany22

Notes:Sources:"Which

ofthese

things

have

youdone

in

the

past12

months?

(multi

pick)

Base:all

respondents

(Health,

Finance,

Insurance)?“;

Multi

Pick;n=

50,398ConsumerInsights

202365%

Germanonline

consumers

experienced

pain

including

backpain,

headacheand

joint

painConsumer

Insights:Regional

Comparison

(4/4)Medical

symptoms

experienced56%Pain(e.g.backpain,headache,jointpain)65%62%44%46%Mentalhealthproblems(e.g.stress,depression,anxiety)33%Sleepdisorders(e.g.problemssleeping

through,problemsfallingasleep)39%42%40%36%38%Coldsymptoms(e.g.runnynose,cough,

sorethroat)48%Digestivecomplaints(e.g.diarrhea,gasandbloating,heartburn)35%35%40%22%21%23%Skin

problems(e.g.skin

rash,

neurodermatitis)17%Ihavenotexperiencedanyofthesemedical

symptoms13%10%UnitedStatesGermanyUnitedKingdom23

Notes:Sources:"Have

youexperienced

any

ofthe

following

medical

symptoms

in

the

past12

months?(multi

pick)

Base:all

respondents

(Health,

Finance,

Insurance)“;

Multi

Pick;n=

50,398ConsumerInsights

2023CHAPTER

3Key

Players24Johnson

&

Johnson

is

one

of

the

major

pharmacy

companies

regardingconsumer

healthcare

revenuesCompany

Profiles

(1/3)Johnson

&Johnson

isamultinationalcompany

specializing

inpharmaceuticals,medical

devices

andconsumer

goods.

Thecompany

operates

inmore

than

60countries

worldwide

andisdivided

into

three

businessmarkets,

which

togetherrealized

atotalrevenue

of

US$94.9

billionin2022.

TheOTC

pharmaceuticalsmarket

accountsfor40%

ofJohnson

&Johnson’stotal

consumer

healthmarketrevenue

in2022.

Theconsumer

market

containssome

of

theworld's

top-sellinghealthcare

brands,including:Listerine,

Neutrogena,

Aveeno,

Motrin,

and

Tylenol.Worldwide

Johnson

&Johnsonshare

ofnetsalesin2022OTC40%Skin

Health/Beauty29%OralCareBabyCare10%10%US$95bnRevenuein2022New

Brunswick,

USHeadquartersWomen’sHealthWoundCare/Other6%152,700employeesin2022US$0.62mRevenuebyemployeein20225%25Sources:

Financial

statements

ofJohnson

&Johnson;

Marketdata

byQuandl

and

WBV

2023;Consumer

Insights

2023GlaxoSmithKline

reported

a

notable

revenue

recovery

in

2022,

experiencing+8%

growthCompany

Profiles

(2/3)GlaxoSmithKline

(GSK),based

inUnitedKingdom,isone

of

the

largestpharmaceutical

companies

worldwide,

with

aturnover

of

nearly

US$36.9

billion

in2022.

Establishedbyamerger

ofGlaxo

Welcome

and

SmithKlineBeecham

in2000,GSKisdividedinto

three

main

businessdivisions:

Pharmaceuticals,

Vaccine

andConsumer

Healthcare.

In2014,

GSKstarted

toinvest

heavily

inemerging

marketsandpaid

US$1

billion

to

raise

itsstakeinitsIndianpharmaceuticalsunit.In2018,GSKboughtNovartis

outof

theirconsumer

healthcare

joint

venture

forUS$13billion.GlaxoSmithKline

total

turnoverinbillionUS$43.743.141.2+8%38.936.934.0Brentford,

UnitedUS$37bnRevenuein2022KingdomHeadquartersUS$0.53mRevenuebyemployeein202269,400

employeesin202220172018201920202021202226Sources:

Financial

statements

ofGSK;Marketdata

by

Quandl

and

WBV

2023;ConsumerInsights

2023Bayer's

Pharmaceuticals

market

sees

decrease

in

revenues

from2021

to

2022Company

Profiles

(3/3)Bayer

AGisaGerman

company

foundedin

1863

byFriedrich

Bayer

andhasnowmore

than

99,000

employees.

TheBayer

Group

is

dividedintothree

divisions:Pharmaceuticals,

Consumer

Health

andCropScience.

Bayer’s

first

and

best-knownproduct

isAspirin.Bayer

AG’stotalrevenue

in2022

was

US$51

andCrop

Scienceisthestrongest

market.

In2016,

Bayer

acquired

Monsanto

forUS$66

billion,anagrochemical

andagriculturalbiotechnology

company.

Thetransaction

wasfinalizedin2018,

aftergetting

the

U.S.andEUregulatory

approval.